Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

Authors not listed

Longeveron Inc. · 2016

Stem-cell exhaustion Stem-cell therapy Human Randomized controlled trial

Abstract

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-23 MST

Cite this

APA

Anonymous. (2016). Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty. <em>Longeveron Inc.</em>. https://clinicaltrials.gov/study/NCT02982915

Vancouver

Anonymous. Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty. Longeveron Inc.. 2016.

BibTeX

@misc{anon2016Effect, title = {Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty}, author = {Anonymous}, journal = {Longeveron Inc.}, year = {2016}, }